{"hands_on_practices": [{"introduction": "The ability of a T cell to recognize an antigen-presenting cell hinges on the stability of the peptide-Major Histocompatibility Complex (pMHC) interaction. This exercise grounds this crucial concept in fundamental biochemical principles. By applying mass-action kinetics, you will derive and calculate the equilibrium state of peptide binding, providing a quantitative lens through which to view the efficiency of antigen loading in the endoplasmic reticulum [@problem_id:2776602].", "problem": "A single peptide species binds reversibly to peptide-receptive Major Histocompatibility Complex (MHC) class I molecules in the endoplasmic reticulum (ER). Consider the bimolecular reaction $M + P \\rightleftharpoons MP$, where $M$ denotes empty MHC, $P$ denotes peptide, and $MP$ denotes the peptide-bound complex. The system follows mass-action kinetics with association rate constant $k_{\\text{on}}$ and dissociation rate constant $k_{\\text{off}}$. Assume a large peptide reservoir such that the free peptide concentration $[P]$ remains effectively constant (pseudo-first-order conditions), and let $[M]$, $[P]$, and $[MP]$ denote the molar concentrations at any time. Let $[M]_{\\text{tot}} = [M] + [MP]$ denote the total MHC concentration, which is conserved.\n\nStarting only from mass-action kinetics and the definition of chemical equilibrium (no additional shortcut formulas), derive an expression for the equilibrium ratio $r$ of empty to peptide-bound MHC, $r \\equiv f_{\\text{empty}}/f_{\\text{bound}}$, where $f_{\\text{empty}} = [M]/[M]_{\\text{tot}}$ and $f_{\\text{bound}} = [MP]/[M]_{\\text{tot}}$.\n\nThen, evaluate $r$ numerically for $[P] = 50\\,\\text{nM}$, $k_{\\text{on}} = 1.0 \\times 10^{5}\\,\\text{M}^{-1}\\text{s}^{-1}$, and $k_{\\text{off}} = 1.0 \\times 10^{-3}\\,\\text{s}^{-1}$. Express your final answer for $r$ as a dimensionless decimal rounded to four significant figures.\n\nBriefly interpret the biological implication of the magnitude of $r$ for the efficiency of antigen presentation to T cells, but report only $r$ as your final numeric answer.", "solution": "The problem is subjected to validation.\n\nStep 1: Extract Givens\n-   The biochemical reaction is a reversible bimolecular binding process: $M + P \\rightleftharpoons MP$.\n-   $M$ represents an empty Major Histocompatibility Complex (MHC) class I molecule.\n-   $P$ represents a peptide.\n-   $MP$ represents the peptide-bound MHC complex.\n-   The system follows mass-action kinetics.\n-   $k_{\\text{on}}$ is the association rate constant.\n-   $k_{\\text{off}}$ is the dissociation rate constant.\n-   Assumption: The concentration of free peptide, $[P]$, is constant.\n-   $[M]_{\\text{tot}} = [M] + [MP]$ is the conserved total MHC concentration.\n-   The objective is to derive an expression for the equilibrium ratio $r \\equiv f_{\\text{empty}}/f_{\\text{bound}}$.\n-   Definitions: $f_{\\text{empty}} = [M]/[M]_{\\text{tot}}$ and $f_{\\text{bound}} = [MP]/[M]_{\\text{tot}}$.\n-   Derivation constraint: Must start from mass-action kinetics and the definition of chemical equilibrium.\n-   Numerical values for evaluation:\n    -   $[P] = 50\\,\\text{nM}$\n    -   $k_{\\text{on}} = 1.0 \\times 10^{5}\\,\\text{M}^{-1}\\text{s}^{-1}$\n    -   $k_{\\text{off}} = 1.0 \\times 10^{-3}\\,\\text{s}^{-1}$\n-   The final answer for $r$ must be a dimensionless decimal rounded to four significant figures.\n-   A brief biological interpretation of the result is requested.\n\nStep 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, describing a standard ligand-receptor binding model common in biochemistry and immunology. It is well-posed, providing all necessary information and clear definitions to arrive at a unique solution. The language is objective and precise. The problem is formalizable, directly relevant to the topic of antigen presentation, and does not contain internal contradictions, unrealistic parameters, or a trivial structure.\n\nStep 3: Verdict and Action\nThe problem is deemed valid. A solution will be furnished.\n\nThe dynamics of the system are described by the law of mass action. The rate of change of the concentration of the peptide-bound MHC complex, $[MP]$, is given by the rate of its formation minus the rate of its dissociation.\n\nThe rate of formation (association) is proportional to the product of the concentrations of the reactants, $[M]$ and $[P]$. Thus, the forward rate is $k_{\\text{on}}[M][P]$.\nThe rate of dissociation (dissociation) is proportional to the concentration of the complex, $[MP]$. Thus, the reverse rate is $k_{\\text{off}}[MP]$.\n\nThe net rate of change of $[MP]$ is therefore described by the following differential equation:\n$$\n\\frac{d[MP]}{dt} = k_{\\text{on}}[M][P] - k_{\\text{off}}[MP]\n$$\nThe problem requires the derivation to start from the definition of chemical equilibrium. At chemical equilibrium, the net rate of change of all species concentrations is zero. Therefore, at equilibrium, we set $\\frac{d[MP]}{dt} = 0$. Let $[M]_{\\text{eq}}$ and $[MP]_{\\text{eq}}$ denote the concentrations at equilibrium.\n$$\nk_{\\text{on}}[M]_{\\text{eq}}[P] = k_{\\text{off}}[MP]_{\\text{eq}}\n$$\nNote that $[P]$ does not have an equilibrium subscript because it is assumed to be constant throughout the process.\n\nThe problem asks for the equilibrium ratio $r \\equiv f_{\\text{empty}}/f_{\\text{bound}}$. We first express this ratio in terms of equilibrium concentrations:\n$$\nr = \\frac{f_{\\text{empty}}}{f_{\\text{bound}}} = \\frac{[M]_{\\text{eq}}/[M]_{\\text{tot}}}{[MP]_{\\text{eq}}/[M]_{\\text{tot}}} = \\frac{[M]_{\\text{eq}}}{[MP]_{\\text{eq}}}\n$$\nWe can rearrange the equilibrium condition to solve for this ratio:\n$$\n\\frac{[M]_{\\text{eq}}}{[MP]_{\\text{eq}}} = \\frac{k_{\\text{off}}}{k_{\\text{on}}[P]}\n$$\nThus, the expression for the ratio $r$ is:\n$$\nr = \\frac{k_{\\text{off}}}{k_{\\text{on}}[P]}\n$$\nThis expression is derived strictly from mass-action kinetics and the definition of equilibrium as required. It is noted that the ratio of rate constants, $k_{\\text{off}}/k_{\\text{on}}$, is the definition of the equilibrium dissociation constant, $K_D$. Therefore, $r = K_D / [P]$.\n\nNext, we evaluate this expression numerically using the provided values. First, all concentrations must be in consistent units, typically Molarity ($\\text{M}$).\nThe peptide concentration is given as $[P] = 50\\,\\text{nM}$. We convert this to $\\text{M}$:\n$$\n[P] = 50\\,\\text{nM} = 50 \\times 10^{-9}\\,\\text{M} = 5.0 \\times 10^{-8}\\,\\text{M}\n$$\nThe rate constants are given as:\n$$\nk_{\\text{on}} = 1.0 \\times 10^{5}\\,\\text{M}^{-1}\\text{s}^{-1}\n$$\n$$\nk_{\\text{off}} = 1.0 \\times 10^{-3}\\,\\text{s}^{-1}\n$$\nSubstituting these values into the expression for $r$:\n$$\nr = \\frac{1.0 \\times 10^{-3}\\,\\text{s}^{-1}}{(1.0 \\times 10^{5}\\,\\text{M}^{-1}\\text{s}^{-1}) \\times (5.0 \\times 10^{-8}\\,\\text{M})}\n$$\nFirst, calculate the product in the denominator:\n$$\n(1.0 \\times 10^{5}) \\times (5.0 \\times 10^{-8}) = 5.0 \\times 10^{5-8} = 5.0 \\times 10^{-3}\n$$\nThe units in the denominator become $(\\text{M}^{-1}\\text{s}^{-1}) \\times \\text{M} = \\text{s}^{-1}$.\nNow, compute the ratio:\n$$\nr = \\frac{1.0 \\times 10^{-3}\\,\\text{s}^{-1}}{5.0 \\times 10^{-3}\\,\\text{s}^{-1}} = \\frac{1.0}{5.0} = 0.2\n$$\nThe units cancel out, so $r$ is dimensionless, as expected for a ratio of fractions.\nThe problem requires the answer to be rounded to four significant figures.\n$$\nr = 0.2000\n$$\nFor the biological interpretation: The ratio $r = 0.2000$ represents the ratio of empty MHC to peptide-bound MHC at equilibrium. A value of $r < 1$ signifies that the concentration of peptide-bound MHC complexes is greater than that of empty MHC molecules. Specifically, $[MP]_{\\text{eq}} = [M]_{\\text{eq}} / r = [M]_{\\text{eq}} / 0.2000 = 5 \\times [M]_{\\text{eq}}$. This indicates that at equilibrium, the population of MHC molecules is predominantly loaded with peptides, with approximately $83.3\\%$ ($1/(1+0.2)$) of the total MHC being in the peptide-bound state. For efficient antigen presentation to T cells, it is critical for a large number of peptide-MHC complexes to be displayed on the antigen-presenting cell surface. A high degree of MHC occupancy, as suggested by this low value of $r$, ensures a strong signal for T cell surveillance and activation, contributing to the efficacy of the adaptive immune response.", "answer": "$$\n\\boxed{0.2000}\n$$", "id": "2776602"}, {"introduction": "While peptide binding affinity is critical, the generation of the peptide epitope itself is a complex, multi-step process. This practice challenges you to move from calculation to experimental design, focusing on the MHC class II pathway and the crucial role of antigen unfolding [@problem_id:2776605]. You will dissect the function of a specific enzyme, predict the outcome of its deficiency, and design a rigorous rescue experiment, honing the critical thinking skills required to probe molecular mechanisms in immunology.", "problem": "You are studying how disulfide bond reduction in endo-lysosomal compartments influences Major Histocompatibility Complex class II (MHC II) antigen processing. Consider the following well-established foundational facts: proteins stabilized by intramolecular disulfide bonds are more resistant to proteolysis until the disulfides are reduced; the MHC II pathway generates peptides from exogenous antigens in acidic endo-lysosomal compartments where cathepsins operate; and Gamma-interferon-inducible lysosomal thiol reductase (GILT) is a lysosomal enzyme that reduces disulfide bonds under acidic conditions, thereby facilitating antigen unfolding and proteolysis before peptide loading onto MHC II guided by Human Leukocyte Antigen-DM (HLA-DM). You compare two protein antigens: Antigen X has $2$ intramolecular disulfide bonds that stabilize the domain containing a known MHC II-restricted epitope; Antigen Y has no cysteines and is known to be processed from a flexible loop region into an MHC II epitope. You pulse dendritic cells with native X or Y and read out Interleukin-$2$ (IL-$2$) production by cognate CD$4^+$ T cell hybridomas as a proxy for MHC II presentation. You test wild-type dendritic cells and GILT-deficient dendritic cells. You also plan a rescue experiment using reducing agents to restore presentation in the GILT-deficient cells but want to avoid globally disturbing MHC II structure or T cell receptor disulfides at the cell surface.\n\nWhich option best predicts the outcome and proposes a scientifically sound, mechanism-based rescue experiment with appropriate controls?\n\nA. In GILT-deficient cells, presentation of Antigen X is selectively reduced, while Antigen Y presentation is unchanged; rescue by pre-reducing purified Antigen X with dithiothreitol (DTT) at acidic pH, followed by alkylation with iodoacetamide to prevent reoxidation, then washing extensively and feeding the pre-reduced/alkylated antigen to GILT-deficient dendritic cells restores presentation of X but not Y; include controls showing unchanged MHC II surface levels and intact presentation of Antigen Y.\n\nB. In GILT-deficient cells, presentation of Antigen X is enhanced because disulfide bonds prevent over-degradation; rescue by adding the oxidant diamide to cultures during antigen pulsing will further stabilize X and increase epitope yield; include a control showing reduced cathepsin activity.\n\nC. In GILT-deficient cells, presentation of both Antigen X and Antigen Y is reduced because GILT is required for lysosomal acidification; rescue by adding chloroquine to neutralize endo-lysosomal pH prevents antigen destruction and restores peptide loading; include a control showing elevated endosomal pH.\n\nD. In GILT-deficient cells, only Major Histocompatibility Complex class I cross-presentation is affected; MHC II presentation of both Antigen X and Antigen Y is unchanged; rescue by adding the proteasome inhibitor MG$132$ shows restoration of class II presentation of X; include a control showing inhibited proteasomal activity.", "solution": "The problem statement will first be subjected to validation.\n\n**Step 1: Extract Givens**\n- **Fact 1**: Proteins stabilized by intramolecular disulfide bonds are more resistant to proteolysis until the disulfides are reduced.\n- **Fact 2**: The Major Histocompatibility Complex class II (MHC II) pathway generates peptides from exogenous antigens in acidic endo-lysosomal compartments where cathepsins operate.\n- **Fact 3**: Gamma-interferon-inducible lysosomal thiol reductase (GILT) is a lysosomal enzyme that reduces disulfide bonds under acidic conditions, facilitating antigen unfolding and proteolysis before peptide loading onto MHC II, a process guided by Human Leukocyte Antigen-DM (HLA-DM).\n- **Antigen X**: Contains $2$ intramolecular disulfide bonds stabilizing the domain with an MHC II-restricted epitope.\n- **Antigen Y**: Contains no cysteines and its MHC II epitope is processed from a flexible loop region.\n- **Experimental System**: Dendritic cells (wild-type and GILT-deficient) are pulsed with native Antigen X or Antigen Y.\n- **Readout**: Interleukin-$2$ (IL-$2$) production by cognate CD$4^+$ T cell hybridomas serves as a proxy for MHC II presentation.\n- **Rescue Experiment Goal**: Restore antigen presentation in GILT-deficient cells using reducing agents, without causing global disturbances like altering MHC II or T cell receptor (TCR) disulfides at the cell surface.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific Grounding**: The problem is based on well-established, fundamental principles of immunology and biochemistry. The described roles of GILT, disulfide bonds in protein stability, the MHC class II pathway, cathepsins, and endo-lysosomal processing are all factually correct and form the basis of current understanding in the field.\n- **Well-Posed**: The problem is clearly structured. It defines two antigens with a key difference (presence/absence of disulfide bonds) and two cell types with a specific genetic deficiency (presence/absence of GILT). It asks for a logical prediction of the experimental outcome and the design of a mechanistically sound rescue experiment. A unique solution based on the provided principles exists.\n- **Objective**: The language is precise, technical, and free of subjective or ambiguous terminology.\n- **Completeness and Consistency**: The provided information is sufficient and self-consistent. The functions of all molecular players are defined, allowing for a logical deduction of their interplay.\n- **Feasibility**: The experimental setup described is standard in cellular immunology research. GILT-deficient models are available, and the proposed techniques (cell culture, T cell assays, protein chemistry) are routine.\n\n**Step 3: Verdict and Action**\nThe problem statement is scientifically sound, well-posed, and complete. It is a valid problem that can be solved through logical deduction from the provided foundational facts.\n\n**Solution Derivation**\nBased on the provided principles, the antigen processing pathways for Antigen X and Antigen Y can be deduced for both wild-type and GILT-deficient dendritic cells (DCs).\n\n1.  **Antigen Y Processing**: Antigen Y lacks disulfide bonds and its epitope is located in a flexible region. This structure makes it readily accessible to proteases. Its processing into an MHC II-binding peptide by cathepsins in the endo-lysosome is therefore independent of disulfide bond reduction. Consequently, the presence or absence of GILT should have no impact on the presentation of Antigen Y.\n\n2.  **Antigen X Processing**: Antigen X is stabilized by intramolecular disulfide bonds. According to the foundational facts, these bonds confer resistance to proteolysis. For the epitope to be excised by cathepsins, the protein must first be unfolded. In wild-type DCs, GILT, being a lysosomal thiol reductase, reduces these disulfide bonds. This leads to the unfolding of Antigen X, rendering it susceptible to proteolysis and allowing for the generation and subsequent loading of its epitope onto MHC II molecules.\n\n3.  **Predicted Outcome in GILT-deficient DCs**: In GILT-deficient DCs, the enzymatic machinery to reduce disulfide bonds within the lysosome is absent. Antigen X will therefore remain in its folded, protease-resistant conformation. Proteolysis by cathepsins will be inefficient, leading to a failure to generate the required peptide epitope. As a result, presentation of the Antigen X epitope on MHC II will be severely reduced or abolished, which will be reflected as a diminished IL-$2$ response from the cognate CD$4^+$ T cells. The presentation of Antigen Y will remain unchanged.\n\n4.  **Design of a Rescue Experiment**: To restore the presentation of Antigen X in GILT-deficient cells, the function of GILT must be bypassed. This can be achieved by pre-treating Antigen X *in vitro* to reduce its disulfide bonds before it is introduced to the cells.\n    - A suitable biochemical procedure involves incubating purified Antigen X with a reducing agent, such as dithiothreitol (DTT), to break the disulfide bonds ($S-S$) into free thiols ($SH$). The problem states GILT works at acidic pH, so performing this step at an acidic pH is a logical choice to mimic the physiological environment.\n    - Upon removal of the reducing agent, the free thiols can re-oxidize in air, re-forming the disulfide bonds. To prevent this, the newly formed thiol groups must be permanently blocked. This is achieved through alkylation, for example, with iodoacetamide (IAA), which covalently modifies the cysteine residues.\n    - The resulting reduced and alkylated Antigen X is now permanently unfolded (in the relevant domains) and will be susceptible to proteolysis even in the absence of GILT. After extensive washing to remove the toxic DTT and IAA, this modified antigen should be efficiently processed and presented by GILT-deficient DCs, thus \"rescuing\" the T cell response.\n    - **Essential Controls**: The experiment must demonstrate that the rescue is specific to the mechanism under investigation. Controls should verify that (i) the overall antigen presentation machinery of the DCs is not non-specifically altered (e.g., surface MHC II levels are constant) and (ii) the presentation of the GILT-independent Antigen Y is not affected, confirming the specificity of the initial defect and the rescue.\n\n**Option-by-Option Analysis**\n\n**A. In GILT-deficient cells, presentation of Antigen X is selectively reduced, while Antigen Y presentation is unchanged; rescue by pre-reducing purified Antigen X with dithiothreitol (DTT) at acidic pH, followed by alkylation with iodoacetamide to prevent reoxidation, then washing extensively and feeding the pre-reduced/alkylated antigen to GILT-deficient dendritic cells restores presentation of X but not Y; include controls showing unchanged MHC II surface levels and intact presentation of Antigen Y.**\n-   **Prediction**: The prediction that presentation of Antigen X is selectively reduced while Antigen Y is unchanged is perfectly aligned with our derivation.\n-   **Rescue Mechanism**: The proposed rescue experiment—pre-reduction with DTT, alkylation with IAA to prevent reoxidation, and washing—is the standard and correct biochemical approach to bypass the need for GILT. It specifically targets the defect. The statement \"restores presentation of X but not Y\" is correctly interpreted as restoring the deficient presentation of X while not affecting the already normal presentation of Y.\n-   **Controls**: The proposed controls—monitoring MHC II surface levels and the presentation of the GILT-independent Antigen Y—are appropriate and necessary to demonstrate the specificity of the effect.\n-   **Verdict**: **Correct**. This option is entirely consistent with the provided scientific principles and describes a methodologically sound experiment.\n\n**B. In GILT-deficient cells, presentation of Antigen X is enhanced because disulfide bonds prevent over-degradation; rescue by adding the oxidant diamide to cultures during antigen pulsing will further stabilize X and increase epitope yield; include a control showing reduced cathepsin activity.**\n-   **Prediction**: The prediction that presentation is *enhanced* is incorrect. Resistance to proteolysis (due to disulfide bonds) *prevents* epitope generation; it does not protect from \"over-degradation\". Lack of GILT will *reduce*, not enhance, presentation.\n-   **Rescue Mechanism**: The proposed rescue is nonsensical. Diamide is an oxidizing agent; it would promote or stabilize disulfide bonds, making the antigen even *more* resistant to proteolysis and further *inhibiting* presentation. This is the opposite of a rescue.\n-   **Verdict**: **Incorrect**. The reasoning is fundamentally flawed and contradicts basic principles of protein chemistry and antigen processing.\n\n**C. In GILT-deficient cells, presentation of both Antigen X and Antigen Y is reduced because GILT is required for lysosomal acidification; rescue by adding chloroquine to neutralize endo-lysosomal pH prevents antigen destruction and restores peptide loading; include a control showing elevated endosomal pH.**\n-   **Prediction**: The premise that GILT is required for lysosomal acidification is factually incorrect. GILT is a reductase; the V-type ATPase is responsible for acidification. Therefore, GILT deficiency should not affect lysosomal pH or the processing of Antigen Y.\n-   **Rescue Mechanism**: The proposed \"rescue\" using chloroquine is incorrect. Chloroquine raises lysosomal pH, which *inactivates* the acid-dependent cathepsins. This would *inhibit* the MHC class II pathway for all protein antigens, not restore it.\n-   **Verdict**: **Incorrect**. This option is based on false premises about the function of both GILT and chloroquine in this context.\n\n**D. In GILT-deficient cells, only Major Histocompatibility Complex class I cross-presentation is affected; MHC II presentation of both Antigen X and Antigen Y is unchanged; rescue by adding the proteasome inhibitor MG132 shows restoration of class II presentation of X; include a control showing inhibited proteasomal activity.**\n-   **Prediction**: The prediction that MHC II presentation is unchanged is in direct contradiction to the provided fact that GILT facilitates processing for MHC II loading. The lack of GILT must affect the MHC II presentation of Antigen X.\n-   **Rescue Mechanism**: The proposed rescue involves the proteasome inhibitor MG$132$. The proteasome is central to the MHC class I pathway, not the canonical MHC class II pathway, which uses lysosomal proteases. Inhibiting the proteasome is irrelevant to correcting a defect in lysosomal unfolding.\n-   **Verdict**: **Incorrect**. This option confuses the MHC class I and class II pathways and proposes an irrelevant rescue mechanism.", "answer": "$$\\boxed{A}$$", "id": "2776605"}, {"introduction": "Modern immunology often moves beyond studying known components to discovering the unknown machinery that governs complex processes like cross-presentation. This advanced problem places you in the role of a research strategist, tasking you with designing a genome-wide CRISPR screen to identify novel host factors involved in this specialized pathway [@problem_id:2776556]. Success requires a deep understanding of the underlying biology to create a specific, high-fidelity screen with airtight controls, reflecting the pinnacle of experimental design in the field.", "problem": "A laboratory wants to discover host genes required specifically for cross-presentation of cell-associated protein antigens. Cross-presentation is defined as the process by which exogenous antigens from other cells are presented on Major Histocompatibility Complex (MHC) class I to activate naive CD$8^+$ T cells. Consider the following foundational facts and definitions as the base for designing a screen:\n- The Central Dogma of molecular biology states that information flows from deoxyribonucleic acid (DNA) to ribonucleic acid (RNA) to protein; protein antigens are processed into peptides by proteases.\n- In the canonical MHC class I pathway, endogenous cytosolic proteins are degraded by the proteasome into peptides, transported into the endoplasmic reticulum (ER) lumen by the Transporter associated with Antigen Processing (TAP), trimmed as needed, and loaded onto MHC class I with participation of peptide-loading complex chaperones. This produces peptide–MHC class I complexes that are trafficked to the cell surface.\n- Cross-presentation of exogenous, cell-associated protein can proceed via an endosome-to-cytosol route that requires antigen export from endosomes to the cytosol and the proteasome–TAP axis, or via a vacuolar route that relies on endo-lysosomal proteases and can be TAP-independent. Dendritic cells (DCs), especially conventional type $1$ DCs, are specialized for cross-presentation.\n- A pooled Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)–CRISPR-associated protein $9$ (Cas9) loss-of-function screen can infer gene function by linking guide representation to a selectable phenotype, provided adequate library coverage, low multiplicity of infection (MOI), appropriate controls, and a readout that directly reflects the biological process under study.\n\nYou are to select one experimental design that would most rigorously and specifically identify host factors required for cross-presentation of cell-associated antigens, while controlling for uptake, general MHC class I surface expression, and non-specific effects on cell viability or activation state. Which option is best?\n\nA. Use Cas9-expressing mouse bone-marrow-derived dendritic cells (BMDCs) transduced at low MOI (target $\\mathrm{MOI}<0.3$) with a genome-wide single guide RNA (sgRNA) library at $>300\\times$ representation. Feed DCs with apoptotic, ovalbumin (OVA)-expressing donor cells labeled with a pH-stable dye to track uptake. After co-culture, stain with the $25$-$\\mathrm{D1.16}$ monoclonal antibody that specifically recognizes the $\\mathrm{H\\text{-}2K^{b}\\text{-}SIINFEKL}$ complex, and perform fluorescence-activated cell sorting (FACS) to isolate the lowest decile of $\\mathrm{H\\text{-}2K^{b}\\text{-}SIINFEKL}$ signal among dye-positive (i.e., phagocytosis-positive), live, $\\mathrm{CD11c^{+}}$ DCs. Sequence sgRNAs enriched in the low-signal fraction to identify candidate genes. In parallel, (i) pulse an aliquot of the same edited DCs with the SIINFEKL peptide to ensure that general MHC class I loading and surface trafficking are intact (candidates that appear only in the cross-presentation arm but not in the peptide-pulsed control are prioritized), and (ii) perform an MHC class II presentation control by feeding OVA protein and co-culturing with OVA$_{323\\text{–}339}$-specific CD$4^+$ T cells to exclude genes acting only through MHC class II. Include Beta-2 microglobulin ($B2m$), Tap1, and proteasome immunosubunits as positive controls expected to reduce the $\\mathrm{H\\text{-}2K^{b}\\text{-}SIINFEKL}$ signal in the cross-presentation arm but not upon peptide pulsing.\n\nB. Use a genome-wide CRISPR screen in an OVA-expressing tumor cell line. Co-culture edited tumor cells with SIINFEKL-specific CD$8^+$ T cells and select for tumor cells that survive T cell killing. Sequence sgRNAs enriched in survivors to identify host factors required for antigen processing and presentation.\n\nC. Use CRISPR interference (CRISPRi) in a DC line. Pulse cells with the SIINFEKL peptide and measure CD$8^+$ T cell activation (interferon-$\\gamma$ release) to read out MHC class I presentation. Controls include knocking down $B2m$ and staining total MHC class I surface levels by flow cytometry.\n\nD. Perform a CRISPR knockout screen in macrophages using fluorescently labeled OVA protein. Sort for cells with low antigen uptake and sequence sgRNAs enriched in the low-uptake population. Validate candidates by measuring total MHC class I levels after peptide pulsing.\n\nChoose the best option.", "solution": "The problem statement must first be validated for scientific soundness, clarity, and internal consistency.\n\n**Step 1: Extract Givens**\n-   **Process of Interest:** Cross-presentation, defined as the presentation of exogenous antigens from other cells on Major Histocompatibility Complex (MHC) class I to activate naive cluster of differentiation $8$ positive ($\\mathrm{CD8^{+}}$) T cells.\n-   **Antigen Source:** Cell-associated protein antigens.\n-   **Biological Principles:**\n    1.  Central Dogma: Deoxyribonucleic acid (DNA) $\\rightarrow$ Ribonucleic acid (RNA) $\\rightarrow$ protein; proteins are processed into peptides by proteases.\n    2.  Canonical MHC class I pathway: Endogenous cytosolic proteins are degraded by the proteasome, transported into the endoplasmic reticulum (ER) by the Transporter associated with Antigen Processing (TAP), and loaded onto MHC class I molecules.\n    3.  Cross-presentation pathways: An endosome-to-cytosol route (requiring antigen export, proteasome, and TAP) and a vacuolar route (using endo-lysosomal proteases, can be TAP-independent).\n    4.  Specialized Cell Type: Dendritic cells (DCs), particularly conventional type $1$ DCs.\n-   **Experimental Method:** Pooled Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)–CRISPR-associated protein $9$ (Cas$9$) loss-of-function screen. Key parameters mentioned are adequate library coverage, low multiplicity of infection (MOI), appropriate controls, and a direct readout.\n-   **Objective:** Identify host genes specifically required for cross-presentation of cell-associated protein antigens, while controlling for antigen uptake, general MHC class I surface expression, and non-specific effects on cell viability or activation state.\n\n**Step 2: Validate Using Extracted Givens**\n-   **Scientific Grounding:** The problem statement is firmly grounded in established principles of immunology and molecular cell biology. The definitions of MHC class I presentation, cross-presentation, and the description of CRISPR-Cas$9$ screening methodology are all factually correct and represent current scientific consensus.\n-   **Well-Posed:** The problem provides a clear and specific objective: to select the best experimental design from a list of options based on a detailed set of criteria (specificity, rigorous controls). The goal is unambiguous.\n-   **Objective:** The language is technical and devoid of subjective or non-scientific content.\n-   **Completeness and Consistency:** The information provided is sufficient to evaluate the proposed experimental designs. There are no internal contradictions. For instance, the acknowledgment of both TAP-dependent and TAP-independent pathways for cross-presentation is an accurate reflection of the biological complexity and does not constitute a contradiction.\n\n**Step 3: Verdict and Action**\nThe problem statement is valid. It is scientifically sound, well-posed, and based on objective, verifiable principles. The task is a rigorous test of understanding experimental design in immunology. I will now proceed with the analysis of the options.\n\nThe objective is to identify the experimental design that most specifically interrogates the machinery of cross-presentation for *cell-associated* protein antigens. This requires:\n$1$. The correct cell type (a professional antigen-presenting cell, or APC, like a DC).\n$2$. The correct antigen source (a protein antigen originating from another cell).\n$3$. A readout that directly measures the outcome of cross-presentation (i.e., peptide-MHC class I complexes on the APC surface).\n$4$. A comprehensive set of controls to exclude genes involved in other processes, such as antigen uptake, canonical MHC class I trafficking, general cell viability, or MHC class II presentation.\n\nNow, I will evaluate each option against these criteria.\n\n**A. Use Cas9-expressing mouse bone-marrow-derived dendritic cells (BMDCs) transduced at low MOI (target $\\mathrm{MOI}<0.3$) with a genome-wide single guide RNA (sgRNA) library at $>300\\times$ representation. Feed DCs with apoptotic, ovalbumin (OVA)-expressing donor cells labeled with a pH-stable dye to track uptake. After co-culture, stain with the $25$-$\\mathrm{D1.16}$ monoclonal antibody that specifically recognizes the $\\mathrm{H\\text{-}2K^{b}\\text{-}SIINFEKL}$ complex, and perform fluorescence-activated cell sorting (FACS) to isolate the lowest decile of $\\mathrm{H\\text{-}2K^{b}\\text{-}SIINFEKL}$ signal among dye-positive (i.e., phagocytosis-positive), live, $\\mathrm{CD11c^{+}}$ DCs. Sequence sgRNAs enriched in the low-signal fraction to identify candidate genes. In parallel, (i) pulse an aliquot of the same edited DCs with the SIINFEKL peptide to ensure that general MHC class I loading and surface trafficking are intact (candidates that appear only in the cross-presentation arm but not in the peptide-pulsed control are prioritized), and (ii) perform an MHC class II presentation control by feeding OVA protein and co-culturing with OVA$_{323\\text{–}339}$-specific CD$4^+$ T cells to exclude genes acting only through MHC class II. Include Beta-2 microglobulin ($B2m$), Tap1, and proteasome immunosubunits as positive controls expected to reduce the $\\mathrm{H\\text{-}2K^{b}\\text{-}SIINFEKL}$ signal in the cross-presentation arm but not upon peptide pulsing.**\n\nThis design is exceptionally rigorous.\n-   **Cell Type:** BMDCs are appropriate professional APCs specialized for cross-presentation.\n-   **Antigen Source:** Apoptotic OVA-expressing cells are a perfect example of a \"cell-associated antigen source,\" mimicking physiological conditions where DCs sample dead or dying cells.\n-   **Readout:** The $25$-$\\mathrm{D1.16}$ antibody provides a direct, quantitative measurement of the specific end product of cross-presentation: the $\\mathrm{H\\text{-}2K^{b}\\text{-}SIINFEKL}$ complex on the DC surface. This is far superior to indirect readouts like T cell activation.\n-   **Controls:** The design includes a full suite of essential controls.\n    -   **Uptake:** Gating on dye-positive cells correctly isolates defects in presentation from upstream defects in phagocytosis.\n    -   **Viability/Cell Type:** Gating on live, $\\mathrm{CD11c^{+}}$ cells ensures data quality and specificity.\n    -   **Canonical MHC I Pathway:** The SIINFEKL peptide-pulse control is crucial. It allows for the specific identification of genes required for processing and transport *prior* to peptide loading in the ER, distinguishing them from genes essential for the general MHC class I pathway (like $B2m$ or TAP).\n    -   **MHC Class II Pathway:** The suggested MHC class II control further refines the specificity of the screen.\n    -   **Positive Controls:** The inclusion of known required genes ($B2m$, Tap1, proteasome subunits) validates the experimental system. The logic for how these controls would behave is sound.\n-   **Screen Parameters:** The mention of low MOI and high library representation indicates a well-planned CRISPR screen.\n\n**Verdict for A:** **Correct**. This option describes a state-of-the-art, highly specific, and rigorously controlled experiment that perfectly matches the stated objective.\n\n**B. Use a genome-wide CRISPR screen in an OVA-expressing tumor cell line. Co-culture edited tumor cells with SIINFEKL-specific CD$8^+$ T cells and select for tumor cells that survive T cell killing. Sequence sgRNAs enriched in survivors to identify host factors required for antigen processing and presentation.**\n\nThis design is fundamentally flawed because it investigates the wrong biological process.\n-   **Process:** The screen is performed in the OVA-expressing tumor cell, which presents an *endogenous* antigen. This is the canonical MHC class I pathway, not cross-presentation. Cross-presentation involves an APC (like a DC) presenting an *exogenous* antigen derived from another cell (like this tumor cell). This experiment screens for genes required for the tumor cell to present its own antigens, not for a DC to cross-present tumor antigens.\n-   **Readout:** T cell killing is an indirect readout that can be affected by numerous escape mechanisms unrelated to antigen presentation (e.g., upregulation of programmed death-ligand $1$ ($\\mathrm{PD-L1}$), downregulation of death receptors, mutations in apoptotic pathways).\n\n**Verdict for B:** **Incorrect**. It fails to investigate cross-presentation.\n\n**C. Use CRISPR interference (CRISPRi) in a DC line. Pulse cells with the SIINFEKL peptide and measure CD$8^+$ T cell activation (interferon-$\\gamma$ release) to read out MHC class I presentation. Controls include knocking down $B2m$ and staining total MHC class I surface levels by flow cytometry.**\n\nThis design is flawed because it bypasses the key steps of the process under investigation.\n-   **Antigen Source:** The experiment uses the pre-processed SIINFEKL peptide. This completely bypasses all the upstream events that define cross-presentation of a protein antigen: uptake of the antigen source, trafficking to a specific compartment, export from that compartment to the cytosol, and proteasomal degradation into peptides. This screen would only identify factors involved in the final steps of peptide loading and surface transport, which are part of the *general* MHC class I pathway, not specific to cross-presentation.\n-   **Goal Mismatch:** The problem explicitly requires identifying factors for \"cross-presentation of cell-associated protein antigens,\" not peptide loading.\n\n**Verdict for C:** **Incorrect**. It does not investigate the processing of a protein antigen, which is a central component of the research question.\n\n**D. Perform a CRISPR knockout screen in macrophages using fluorescently labeled OVA protein. Sort for cells with low antigen uptake and sequence sgRNAs enriched in the low-uptake population. Validate candidates by measuring total MHC class I levels after peptide pulsing.**\n\nThis design is flawed for two major reasons.\n-   **Screen objective:** The screen is designed to sort for cells with *low antigen uptake*. Therefore, it will identify genes required for endocytosis or phagocytosis, not for antigen processing or presentation. The goal is to find genes for presentation, controlling for uptake, not the other way around.\n-   **Antigen Source:** It uses soluble OVA protein, not a \"cell-associated\" antigen source as specified in the problem statement. The pathways for processing soluble versus particulate/cell-associated antigens can differ.\n\n**Verdict for D:** **Incorrect**. The primary selection criterion (low uptake) is misaligned with the scientific question (defective presentation).\n\nIn conclusion, Option A is the only one that proposes an experimental design that is both specific to the biological question of cross-presentation of cell-associated antigens and includes the necessary rigorous controls to ensure the validity and specificity of the results. The other options either investigate the wrong process (B), bypass the key steps (C), or select for the wrong phenotype (D).", "answer": "$$\\boxed{A}$$", "id": "2776556"}]}